Isodiol International Inc. (CSE: ISOL ) (OTCQB: ISOLF ) (FSE: LB6A.F ) announced today it will be launching Pawceuticals , a CBD-based product line that naturally aids in restoring a pet’s health and improving overall wellness.

The Pawceuticals functional CBD pet products are designed for dogs and cats and are scientifically formulated with a proprietary blend of adaptogens that may aid in comfort, calming, healthy gums support, immune support, itch support, joint support, kennel cough support, kidney support, liver support, urinary support and anti-aging. The Company anticipates these products will be available for purchase online in late November at Pawceuticals.com .

“Pet owners are more passionate than ever about the health and wellness of their pets,” said CEO of Isodiol Marcos Agramont. “Pet owners today prefer products that are all natural and less harmful than standard veterinary prescribed medications. CBD offers powerful benefits especially when combined with other adaptogens to help maintain and improve a pet’s health and overall wellness without producing unwanted side effects.”

Isodiol believes in providing all-natural CBD products to the public by continuously striving to create cutting-edge products that can offer happiness, health and protection for all members of the household, including pets.

For more information on Isodiol, please visit www.isodiol.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was announced April 26, 2018 .

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook: https://www.facebook.com/IsodiolInternationalInc/

Twitter: @Isodiolintlinc

ON BEHALF OF THE BOARD

Marcos Agramont, CEO & Director

INVESTOR RELATIONS:

Ir@isodiol.com

www.isodiol.com

MEDIA CONTACT:

KCSA Strategic Communications

www.KCSA.com

isodiol@kcsa.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.